Literature DB >> 21031518

Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer.

Savannah C Partridge1, Risa K Vanantwerp, Robert K Doot, Xiaoyu Chai, Brenda F Kurland, Peter R Eby, Jennifer M Specht, Lisa K Dunnwald, Erin K Schubert, Constance D Lehman, David A Mankoff.   

Abstract

PURPOSE: To investigate the relationship between changes in vascularity and metabolic activity measured by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and dynamic (18)F-FDG-positron emission tomography (PET) in breast tumors undergoing neoadjuvant chemotherapy.
MATERIALS AND METHODS: PET and MRI examinations were performed in 14 patients with locally advanced breast cancer (LABC) before and after chemotherapy. Dynamic (18)F-FDG PET measures included (18)F-FDG transport rate constant from blood to tissue (K(1)) and metabolism flux constant (Ki). DCE-MRI measures included initial peak enhancement (PE), signal enhancement ratio (SER), and tumor volume. Spearman rank-order correlations were assessed between changes in PET and MRI parameters, and measures were compared between patients with and without pathologic complete response (pCR) by Mann-Whitney U-test.
RESULTS: Changes in glucose delivery (PET K(1)) were closely correlated with changes in tumor vascularity as reflected by DCE-MRI SER (r = 0.83, P < 0.001). Metabolic changes in PET Ki showed moderate correlations with vascularity changes as reflected by SER (r = 0.71) and PE (r = 0.76), and correlated closely with MRI tumor volume (r = 0.79, P < 0.001). Decreases in K(1), Ki, SER, and PE were greater for patients with pCR compared to those with residual disease (P < 0.05).
CONCLUSION: Dynamic (18)F-FDG PET and DCE-MRI tumor measures of tumor metabolism, vascularity, and volume were well correlated for assessing LABC response to neoadjuvant chemotherapy and significantly discriminated pathologic complete responders. Further work is necessary to assess the value of combined PET and MRI for evaluating tumor pharmacodynamics in response to novel therapy.
© 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21031518      PMCID: PMC2967415          DOI: 10.1002/jmri.22362

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  29 in total

1.  MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival.

Authors:  Savannah C Partridge; Jessica E Gibbs; Ying Lu; Laura J Esserman; Debasish Tripathy; Dulcy S Wolverton; Hope S Rugo; E Shelley Hwang; Cheryl A Ewing; Nola M Hylton
Journal:  AJR Am J Roentgenol       Date:  2005-06       Impact factor: 3.959

2.  Monitoring primary breast cancer throughout chemotherapy using FDG-PET.

Authors:  Garry M McDermott; Andrew Welch; Roger T Staff; Fiona J Gilbert; Lutz Schweiger; Scott I K Semple; Tim A D Smith; Andrew W Hutcheon; Iain D Miller; Ian C Smith; Steven D Heys
Journal:  Breast Cancer Res Treat       Date:  2006-08-09       Impact factor: 4.872

3.  The [18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man.

Authors:  M Reivich; D Kuhl; A Wolf; J Greenberg; M Phelps; T Ido; V Casella; J Fowler; E Hoffman; A Alavi; P Som; L Sokoloff
Journal:  Circ Res       Date:  1979-01       Impact factor: 17.367

4.  18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy.

Authors:  Jeffrey Tseng; Lisa K Dunnwald; Erin K Schubert; Jeanne M Link; Satoshi Minoshima; Mark Muzi; David A Mankoff
Journal:  J Nucl Med       Date:  2004-11       Impact factor: 10.057

5.  Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy.

Authors:  David A Mankoff; Lisa K Dunnwald; Julie R Gralow; Georgiana K Ellis; Aaron Charlop; Thomas J Lawton; Erin K Schubert; Jeffrey Tseng; Robert B Livingston
Journal:  J Nucl Med       Date:  2002-04       Impact factor: 10.057

6.  Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor Histopathology and Angiogenesis in Breast Carcinoma.

Authors:  Laura Esserman; Nola Hylton; Tracy George; Noel Weidner
Journal:  Breast J       Date:  1999-01       Impact factor: 2.431

7.  The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.

Authors:  Amandeep Kumar; Rakesh Kumar; Vathalaru Seenu; Sidharatha Datta Gupta; Madhavi Chawla; Arun Malhotra; Sada Nand Mehta
Journal:  Eur Radiol       Date:  2009-02-13       Impact factor: 5.315

8.  The relationship between vascular and metabolic characteristics of primary breast tumours.

Authors:  Scott I K Semple; Fiona J Gilbert; Thomas W Redpath; Roger T Staff; Trevor S Ahearn; Andrew E Welch; Steven D Heys; Andrew W Hutcheon; Elizabeth H Smyth; Shailesh Chaturvedi
Journal:  Eur Radiol       Date:  2004-08-14       Impact factor: 5.315

9.  Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results.

Authors:  Anwar R Padhani; Carmel Hayes; Laura Assersohn; Trevor Powles; Andreas Makris; John Suckling; Martin O Leach; Janet E Husband
Journal:  Radiology       Date:  2006-03-16       Impact factor: 11.105

10.  Dual-time-point 18F-FDG PET/CT versus dynamic breast MRI of suspicious breast lesions.

Authors:  Massimo Imbriaco; Maria Grazia Caprio; Gennaro Limite; Leonardo Pace; Teresa De Falco; Ermanno Capuano; Marco Salvatore
Journal:  AJR Am J Roentgenol       Date:  2008-11       Impact factor: 3.959

View more
  21 in total

Review 1.  In vivo optical imaging and dynamic contrast methods for biomedical research.

Authors:  Elizabeth M C Hillman; Cyrus B Amoozegar; Tracy Wang; Addason F H McCaslin; Matthew B Bouchard; James Mansfield; Richard M Levenson
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2011-11-28       Impact factor: 4.226

Review 2.  Neoadjuvant chemotherapy in breast cancers.

Authors:  Shahla Masood
Journal:  Womens Health (Lond)       Date:  2016-09

3.  Intratumor partitioning and texture analysis of dynamic contrast-enhanced (DCE)-MRI identifies relevant tumor subregions to predict pathological response of breast cancer to neoadjuvant chemotherapy.

Authors:  Jia Wu; Guanghua Gong; Yi Cui; Ruijiang Li
Journal:  J Magn Reson Imaging       Date:  2016-04-15       Impact factor: 4.813

4.  The combination of FDG PET and dynamic contrast-enhanced MRI improves the prediction of disease-free survival in patients with advanced breast cancer after the first cycle of neoadjuvant chemotherapy.

Authors:  Ilhan Lim; Woo Chul Noh; Jihyun Park; Ji Ae Park; Hyun-Ah Kim; Eun-Kyu Kim; Ko Woon Park; Seung Sook Lee; Eun Young You; Kyeong Min Kim; Byung Hyun Byun; Byung Ii Kim; Chang Woon Choi; Sang Moo Lim
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-06-14       Impact factor: 9.236

Review 5.  Breast PET/MR Imaging.

Authors:  Amy Melsaether; Linda Moy
Journal:  Radiol Clin North Am       Date:  2017-02-01       Impact factor: 2.303

6.  ¹⁸F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study.

Authors:  Flavio Crippa; Roberto Agresti; Marco Sandri; Gabriella Mariani; Barbara Padovano; Alessandra Alessi; Giulia Bianchi; Emilio Bombardieri; Ilaria Maugeri; Mario Rampa; Maria Luisa Carcangiu; Giovanna Trecate; Claudio Pascali; Anna Bogni; Gabriele Martelli; Filippo de Braud
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-12       Impact factor: 9.236

7.  Accuracy of 3 T versus 1.5 T breast MRI for pre-operative assessment of extent of disease in newly diagnosed DCIS.

Authors:  Habib Rahbar; Wendy B DeMartini; Amie Y Lee; Savannah C Partridge; Sue Peacock; Constance D Lehman
Journal:  Eur J Radiol       Date:  2015-01-08       Impact factor: 3.528

8.  Combined use of ¹⁸F-FDG PET/CT and MRI for response monitoring of breast cancer during neoadjuvant chemotherapy.

Authors:  Kenneth E Pengel; Bas B Koolen; Claudette E Loo; Wouter V Vogel; Jelle Wesseling; Esther H Lips; Emiel J Th Rutgers; Renato A Valdés Olmos; Marie Jeanne T F D Vrancken Peeters; Sjoerd Rodenhuis; Kenneth G A Gilhuijs
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04-29       Impact factor: 9.236

9.  Optimized breast MRI functional tumor volume as a biomarker of recurrence-free survival following neoadjuvant chemotherapy.

Authors:  Nazia F Jafri; David C Newitt; John Kornak; Laura J Esserman; Bonnie N Joe; Nola M Hylton
Journal:  J Magn Reson Imaging       Date:  2013-12-18       Impact factor: 4.813

10.  International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013).

Authors:  Vito Amoroso; Daniele Generali; Thomas Buchholz; Massimo Cristofanilli; Rebecca Pedersini; Giuseppe Curigliano; Maria Grazia Daidone; Serena Di Cosimo; Mitchell Dowsett; Stephen Fox; Adrian L Harris; Andreas Makris; Lucia Vassalli; Andrea Ravelli; Maria Rosa Cappelletti; Christos Hatzis; Clifford A Hudis; Paolo Pedrazzoli; Anna Sapino; Vladimir Semiglazov; Gunter Von Minckwitz; Edda L Simoncini; Michael A Jacobs; Peter Barry; Thorsten Kühn; Sarah Darby; Kerstin Hermelink; Fraser Symmans; Alessandra Gennari; Gaia Schiavon; Luigi Dogliotti; Alfredo Berruti; Alberto Bottini
Journal:  J Natl Cancer Inst Monogr       Date:  2015-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.